TRT and erythrocytosis: what thicker blood actually means

What's this video probably claiming?

A urology practice posting about testosterone and erythrocytosis is almost certainly walking viewers through one of TRT's most documented side effects: the tendency of exogenous testosterone to stimulate red blood cell production, raising hematocrit and hemoglobin levels. Based on the hashtags and creator context, the video likely frames this as a manageable, well-understood phenomenon rather than a reason to avoid TRT entirely. The creator is probably explaining why patients get blood work done regularly on therapy, what hematocrit thresholds matter clinically, and possibly what interventions exist, such as dose reduction or therapeutic phlebotomy. Urology-based TRT accounts tend toward the reassuring end of this conversation, which is not automatically wrong, but warrants scrutiny. The framing of erythrocytosis as simply "thicker blood" is technically loose, and whether the video quantifies actual risk or just normalizes the side effect without adequate context will matter a great deal.

What does the science actually show?

Testosterone-induced erythrocytosis is well-documented and dose-dependent. A 2010 meta-analysis by Calof et al. in the Journals of Gerontology found erythrocytosis occurring in roughly 5.7% of men on testosterone therapy versus 0% in placebo groups. Injection-based testosterone, particularly cypionate and enanthate, produces more pronounced hematocrit elevation than gels or patches, likely because of peak-and-trough pharmacokinetics driving erythropoietin stimulation. The Endocrine Society's 2018 clinical practice guidelines recommend withholding or reducing testosterone when hematocrit exceeds 54%. Studies like Yassin et al. (2013, World Journal of Urology) confirm that most hematocrit elevation stabilizes within 3-6 months of starting therapy, but that does not mean it resolves. Secondary erythrocytosis raises theoretical cardiovascular risk through increased blood viscosity, though a direct causal link to thrombotic events in otherwise healthy TRT users remains contested in the literature. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no statistically significant increase in major cardiovascular events in TRT users versus placebo, but erythrocytosis was among the more common adverse events reported.

Where does the social media noise diverge from clinical reality?

The TRT optimization community on TikTok has a consistent pattern of treating erythrocytosis as a minor inconvenience rather than a genuine monitoring priority. You will regularly see claims that hematocrit up to 55 or 56 percent is "fine" if the patient feels good, which has no clinical basis. There is also widespread promotion of therapeutic phlebotomy as a routine self-management tool, sometimes disconnected from physician oversight, which is a problem. Phlebotomy does lower hematocrit, but it also depletes iron stores, and repeated phlebotomy in otherwise iron-replete men can create secondary iron deficiency, potentially worsening fatigue, the very symptom TRT is meant to address. Conversely, fear-based content overstates stroke and clot risk without distinguishing between polycythemia vera, a malignant condition, and the secondary erythrocytosis TRT produces. These are not the same pathology and should not be discussed as equivalent. The actual clinical threshold, monitoring schedule, and dose adjustment strategy tend to get lost in both the reassuring and alarmist versions of this content.

What should you actually know?

If you are on injectable testosterone and your hematocrit is climbing, that is not automatically a crisis, but it is not something to dismiss based on a TikTok either. The standard of care involves hematocrit monitoring at 3 and 6 months after initiation, then annually if stable. The 54% threshold from the Endocrine Society is not arbitrary, it reflects a viscosity inflection point where thrombotic risk becomes clinically meaningful. Switching from injections to transdermal delivery genuinely reduces erythrocytosis risk in many patients, a point supported by comparative pharmacokinetic data. If your prescriber is not checking your complete blood count on a regular basis, that is a gap in your care. Self-managing this side effect based on social media guidance, including scheduling your own phlebotomies without monitoring iron stores, introduces risks that are entirely avoidable with proper oversight. Dose, delivery method, and individual variation all affect how significantly your hematocrit responds to testosterone.